Výsledky vyhledávání - "MESH: Prostate-Specific Antigen"

Relevance of total PSA and free PSA prescriptions

Autor: Sylvain Loric, Laurent Bermont, Jean-Paul Brouillet, Pierre-Jean Lamy, Guy Fouillet

Publikováno v: Annales de Biologie Clinique
Annales de Biologie Clinique, John Libbey Eurotext, 2018, 76 (6), pp.659-663. ⟨10.1684/abc.2018.1392⟩

International audience; The total PSA testing has been frequently criticized for its effectiveness in the early detection of prostate cancer. These widely resumed in and out of the medical community have led to a decrease in prescriptions. Recommenda

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bca904afce44c019c37fb0675f20f8
https://hal.umontpellier.fr/hal-02289877

Zobrazit plný text záznamu

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy

Autor: Serge Koscielny, François Eschwege, Pierre Wibault, Khemaies Slimane, Alberto Bossi, T. Messai, R. de Crevoisier, André Bridier, Karim Fizazi, Christophe Massard

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2010, 21 (4), pp.808-14. ⟨10.1093/annonc/mdp365⟩

International audience; BACKGROUND: The aim was to identify predictors of outcome in patients with localized prostate cancer treated with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT). Materials and methods: A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df7f369a2e57a159ab1c0c5505babbc
https://doi.org/10.1093/annonc/mdp365

Zobrazit plný text záznamu

Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—A new paradigm for cooperation among prostate tumor cells

Autor: Audrey Monge, Gemma Marcias, Pascal Kessler, Eva Erdmann, Gaëlle Lapouge, Sebastian Serra, Hervé Lang, Monika Jagla, Jocelyn Céraline, Jean-Pierre Bergerat, Didier Jacqmin

Publikováno v: International Journal of Cancer
International Journal of Cancer, Wiley, 2007, 121 (6), pp.1238-44. ⟨10.1002/ijc.22830⟩

The emergence of mutations in the androgen receptor (AR) gene is a recurrent event during progression of prostate cancer (PCa) on androgen ablation therapy. In this study, we show that nonsense mutations that lead to carboxyl-terminal end truncated A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd7394c6091838adad4f136af21e1b19
https://doi.org/10.1002/ijc.22830

Zobrazit plný text záznamu

Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology

Autor: Mathilde Funes de la Vega, Céline Mirjolet, Philippe Maingon, Alexandre Cochet, Paul Walker, François Brunotte, Douraied Ben Salem, Sébastien Parfait, Franck Bonnetain, Mélanie Liegard, Gilles Créhange, Luc Cormier

Publikováno v: International Journal of Radiation Oncology-Biology-Physics
International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2011, 80 (4), pp.1087-1094. ⟨10.1016/j.ijrobp.2010.03.007⟩
International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2011, 80 (4), pp.1087-94. ⟨10.1016/j.ijrobp.2010.03.007⟩
International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2011, 80 (4), pp.1087-94. 〈10.1016/j.ijrobp.2010.03.007〉
International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2011, 80 (4), pp.1087-1094. 〈10.1016/j.ijrobp.2010.03.007〉

International audience; Abstract PURPOSE: To determine whether a relationship exists between the tumor volume (TV) or relative choline content determined using magnetic resonance spectroscopy imaging (MRSI) at 3T and the clinical prognostic parameter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5915f566c3cf395372d5629d8d85309a
https://hal.archives-ouvertes.fr/hal-00785884

Zobrazit plný text záznamu

Effect of dutasteride on the risk of prostate cancer

Autor: Andriole, G.L., Bostwick, D.G., Brawley, O.W., Gomella, L.G., Marberger, M., Montorsi, F., Pettaway, C.A., Tammela, T.L.J., Teloken, C., Tindall, D.J., Somerville, M.C., Wilson, T.H., Fowler, I.L., Rittmaster, R.S., Mulders, P.F.A., Schrier, B.P.

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (13), pp.1192-1202. 〈10.1056/NEJMoa0908127〉
The New England Journal of Medicine, 362, 13, pp. 1192-202
The New England Journal of Medicine, 362, 1192-202
New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (13), pp.1192-1202. ⟨10.1056/NEJMoa0908127⟩

Background: We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Methods: In this 4-year, multicenter, randomized, double-blind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6fa3ab27f971d1b316531701f9a115c
https://hal.archives-ouvertes.fr/hal-00493661

Zobrazit plný text záznamu

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure

Autor: Ladoire, Sylvain, Eymard, Jean-Christophe, Zanetta, Sylvie, Mignot, Grégoire, Martin, Etienne, Kermarrec, Isabelle, Mourey, Eric, Michel, Frédéric, Cormier, Luc, Ghiringhelli, François

Publikováno v: Anticancer Research
Anticancer Research, International Institute of Anticancer Research, 2010, 30 (10), pp.4317-23

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cycloph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e034c3bb6041cd0a5aa4be9b69c5237f
https://www.hal.inserm.fr/inserm-00555027

Zobrazit plný text záznamu

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

Autor: Studer , Urs E, Collette , Laurence, Whelan , Peter, Albrecht , Walter, Casselman , Jacques, De Reijke , Theo, Knönagel , Hartmut, Loidl , Wolfgang, Isorna , Santiago, Sundaram , Subramanian K, Debois , Muriel, Renseigné , Non, Bittard , Hugues

Publikováno v: European Urology
European Urology, Elsevier, 2008, 53 (5), pp.941-949. 〈10.1016/j.eururo.2007.12.032〉
European Urology, Elsevier, 2008, 53 (5), pp.941-949. ⟨10.1016/j.eururo.2007.12.032⟩
European urology, 53(5), 941-949. Elsevier

OBJECTIVE: EORTC trial 30891 compared immediate versus deferred androgen-deprivation therapy (ADT) in T0-4 N0-2 M0 prostate cancer (PCa). Many patients randomly assigned to deferred ADT did not require ADT because they died before becoming symptomati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fb2f9c14188057a22030522091131b
https://hal.archives-ouvertes.fr/hal-00485606

Zobrazit plný text záznamu

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911

Autor: Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L, and EORTC 22911

Publikováno v: Journal of clinical oncology, 25(27), 4178-4186. American Society of Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2007, 25 (27), pp.4178-4186. 〈10.1200/JCO.2006.10.4067〉
Journal of Clinical Oncology, American Society of Clinical Oncology, 2007, 25 (27), pp.4178-4186. ⟨10.1200/JCO.2006.10.4067⟩
Journal of Clinical Oncology, 25(27), 4178-4186. American Society of Clinical Oncology

Purpose The randomized controlled European Organisation for Research and Treatment of Cancer (EORTC) trial 22911 studied the effect of radiotherapy after prostatectomy in patients with adverse risk factors. Review pathology data of specimens from par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91dbd991b77b8e93709ad422aaf159ba
https://pubmed.ncbi.nlm.nih.gov/18441534

Zobrazit plný text záznamu

[The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity]

Publikováno v: Cancer Radiothérapie
Cancer Radiothérapie, Elsevier Masson, 2006, 10 (8), pp.559-564. ⟨10.1016/j.canrad.2006.07.008⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, 2006, 10 (8), pp.559-564. ⟨10.1016/j.canrad.2006.07.008⟩
Cancer Radiothérapie, Elsevier Masson, 2006, 10 (8), pp.559-564. 〈10.1016/j.canrad.2006.07.008〉

International audience; PURPOSE: To analyse a new technique for prostate brachytherapy with permanent Iodine implants characterized by the use of a seed projector after a 3D dosimetric peroperative treatment planning (FIRST technique). PATIENTS AND M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b8cbe5a14009f4ea59d85c0c19521c93
https://hal.archives-ouvertes.fr/hal-00486781

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání